INVITRO INTERNATIONAL REPORTS 1ST
HALF 2000 OPERATING INCOME
ON INCREASED SALES;
U.S. Government Agency Approvals expected to brighten future

Irvine,
CA May 16, 2000 -- InVitro International (IVRO) announced
today that revenues for each of its first two fiscal
quarters in 2000 advanced to slightly more than $168,000.
The nearly $337,000 first half sales total represents an
increase of about 3% over same period 1999 figures. Operating
profits for the December quarter were $7,787, and for the
March quarter $13,967. These two quarters' results extend
to six, the number of consecutive fiscal quarters that IVRO
has posted operating income. Although net income in IVRO's
second quarter was $8,949, the company posted a first half
2000 net loss of $95,249 due to an extraordinary, non-recurring
write-off of $115,000 for a single doubtful receivable.
In commenting on first half
Y2K results, InVitro President, W. Richard Ulmer, said,
"We were really quite pleased with overall financial
progress in our core business. And we are particularly hopeful
that the recent approvals and acceptances from several important
U.S. Regulatory Agencies (EPA, FDA, Consumer Product Safety
Commission & OSHA) will reinvigorate our now 15 year old
non-animal testing business. Such approvals reflect exciting
scientific support and validation that should help Corrositex
more firmly establish itself as the only commercially available
government approved alternative to animal testing for corrosion.
We plan to extend such strong credibility to include our
other core capability, the Irritection Assay System, for
ocular and dermal irritation detection."
This press release may contain
"forward-looking statements" as defined in the Private Securities
Litigation Reform Act of 1995. Actual results may differ
materially from those projected as a result of certain risks
and uncertainties. These risks and uncertainties include,
but are not limited to: acceptance of the Company's technology
by customers or regulatory agencies, changes in market conditions
and other competitive factors. Any such forward-looking
statements are not guarantees of future performance.